Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal cancers

Bibliography

• Vineis P, Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 2007;16:1954-65
   PubMed Web of Science ®Google Scholar
• Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935-53
   PubMed Web of Science ®Google Scholar
• Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986;104:66-73
   PubMed Web of Science ®Google Scholar
• Duffy MJ, van Dalen A, Haglund C, Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-27
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001;47:624-30
   PubMed Web of Science ®Google Scholar
• Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999;26:556-60
   PubMed Web of Science ®Google Scholar
• Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006;20:579-87
   PubMed Web of Science ®Google Scholar
• Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338-51
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, ; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Basenau D, Holthusen S, Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997;17:3153-6
   PubMed Web of Science ®Google Scholar
• Schneider J, Bitterlich N, Schulze G. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res 2005;25(3A):1507-15
   PubMed Web of Science ®Google Scholar
• Kumar Y, Tapuria N, Kirmani N, Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007;19:265-76
   PubMed Web of Science ®Google Scholar
• Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 2007;14:2714-20
   PubMed Web of Science ®Google Scholar
• Sagiv E, Arber N. The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepatol 2008;2:125-33
   PubMedGoogle Scholar
• Sagiv E, Memeo L, Karin A, CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006;131:630-9
   PubMed Web of Science ®Google Scholar
• Sagiv E, Starr A, Rozovski U, Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008;8:2803-12
   Google Scholar
• Bussom S, Saif MW. Methods and rationale for the early detection of pancreatic cancer. Highlights from the ‘2010 ASCO Gastrointestinal Cancers Symposium’. Orlando, FL, USA. January 22–24, 2010. JOP 2010;11:128-30
   Google Scholar
• Ni XG, Bai XF, Mao YL, The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31:164-9
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000;15:343-56
   PubMed Web of Science ®Google Scholar
• Gold DV, Karanjawala Z, Modrak DE, PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007;13:7380-7
   PubMed Web of Science ®Google Scholar
• Gold DV, Modrak DE, Ying Z, New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006;24:252-8
   PubMed Web of Science ®Google Scholar
• Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J Cell Biochem 2004;91:365-74
   PubMed Web of Science ®Google Scholar
• Leman ES, Schoen RE, Weissfeld JL, Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007;67:5600-5
   PubMed Web of Science ®Google Scholar
• Walgenbach-Brunagel G, Burger B, Leman ES, The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J Cell Biochem 2008;104:286-94
   PubMed Web of Science ®Google Scholar
• Leman ES, Schoen RE, Magheli A, Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res 2008;14:1349-54
   PubMed Web of Science ®Google Scholar
• Stein U, Arlt F, Walther W, The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006;131:1486-500
   Google Scholar
• Fraga MF, Ballestar E, Paz MF, Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604-9
   PubMed Web of Science ®Google Scholar
• Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA 2008;299:1345-50
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50
   PubMed Web of Science ®Google Scholar
• Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Koi M, Kloor M, Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 2008;134:1950-60, 1960
   PubMed Web of Science ®Google Scholar
• Shin SK, Nagasaka T, Jung BH, Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology 2007;133:1849-57
   PubMed Web of Science ®Google Scholar
• Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005;15:490-5
   PubMed Web of Science ®Google Scholar
• Balaguer F, Link A, Lozano JJ, Epigenetic Silencing of miR-137 Is an Early Event in Colorectal Carcinogenesis. Cancer Res 2010;70(16):6609-18
   Google Scholar
• Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-19
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Goel A, Matsubara N, Detection of fecal DNA methylation for colorectal neoplasia: does it lead to an optimal screening test? Acta Med Okayama 2006;60:249-56
   PubMed Web of Science ®Google Scholar
• Goel A. DNA methylation-based fecal biomarkers for the noninvasive screening of GI cancers. Future Oncol 2010;6:333-6
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Tanaka N, Cullings HM, Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009;101:1244-58
   PubMedGoogle Scholar
• Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92
   PubMed Web of Science ®Google Scholar
• Katsnelson A. Genomics goes beyond DNA sequence [Abstract]. Nature 2010;465(7295):145
   PubMed Web of Science ®Google Scholar
• Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-2
   PubMed Web of Science ®Google Scholar
• Wallner M, Herbst A, Behrens A, Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006;12:7347-52
   PubMed Web of Science ®Google Scholar
• Nakayama H, Hibi K, Takase T, Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 2003;105:491-3
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Man EP, Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005;100:2274-9
   PubMed Web of Science ®Google Scholar
• Zou HZ, Yu BM, Wang ZW, Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 2002;8:188-91
   PubMed Web of Science ®Google Scholar
• Nakayama H, Hibi K, Taguchi M, Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 2002;188:115-19
   PubMed Web of Science ®Google Scholar
• Nakayama G, Hibi K, Kodera Y, P16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma. Anticancer Res 2007;27(5A):3367-70
   PubMed Web of Science ®Google Scholar
• Nakayama G, Hibi K, Nakayama H, A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients. Anticancer Res 2007;27(3B):1459-63
   PubMed Web of Science ®Google Scholar
• Bazan V, Bruno L, Augello C, Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006;17(Suppl 7):vii84-90
   PubMedGoogle Scholar
• Yamaguchi S, Asao T, Nakamura J, High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett 2003;194:99-105
   PubMed Web of Science ®Google Scholar
• Tan SH, Ida H, Lau QC, Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007;18:1225-30
   PubMed Web of Science ®Google Scholar
• Wang YC, Yu ZH, Liu C, Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 2008;14:3074-80
   PubMed Web of Science ®Google Scholar
• Ebert MP, Model F, Mooney S, Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006;131:1418-30
   PubMed Web of Science ®Google Scholar
• Lofton-Day C, Model F, Devos T, DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008;54:414-23
   PubMed Web of Science ®Google Scholar
• Sabbioni S, Miotto E, Veronese A, Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol Diagn 2003;7:201-7
   Google Scholar
• Herbst A, Wallner M, Rahmig K, Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol 2009;21:565-9
   PubMed Web of Science ®Google Scholar
• Grutzmann R, Molnar B, Pilarsky C, Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008;3:e3759
   PubMed Web of Science ®Google Scholar
• Devos T, Tetzner R, Model F, Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009;55:1337-46
   PubMed Web of Science ®Google Scholar
• Ally MS, Al-Ghnaniem R, Pufulete M. The relationship between gene-specific DNA methylation in leukocytes and normal colorectal mucosa in subjects with and without colorectal tumors. Cancer Epidemiol Biomarkers Prev 2009;18:922-8
   Google Scholar
• Lee BB, Lee EJ, Jung EH, Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009;15(19):6185-91
   PubMed Web of Science ®Google Scholar
• Li M, Chen WD, Papadopoulos N, Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009;27:858-63
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59
   PubMed Web of Science ®Google Scholar
• Vu TH, Nguyen AH, Hoffman AR. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum Mol Genet 2010;19:901-19
   PubMed Web of Science ®Google Scholar
• Cui H, Cruz-Correa M, Giardiello FM, Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5
   PubMed Web of Science ®Google Scholar
• Lee TL, Leung WK, Chan MW, Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002;8:1761-6
   PubMed Web of Science ®Google Scholar
• Kanyama Y, Hibi K, Nakayama H, Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci 2003;94:418-20
   PubMed Web of Science ®Google Scholar
• Sakakura C, Hamada T, Miyagawa K, Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res 2009;29:2619-25
   PubMed Web of Science ®Google Scholar
• Ichikawa D, Koike H, Ikoma H, Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res 2004;24:2477-81
   PubMed Web of Science ®Google Scholar
• Koike H, Ichikawa D, Ikoma H, Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. Hepatogastroenterology 2005;52:1293-6
   PubMed Web of Science ®Google Scholar
• Ikoma H, Ichikawa D, Koike H, Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res 2006;26(3B):2313-16
   PubMed Web of Science ®Google Scholar
• Ikoma H, Ichikawa D, Daito I, Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology 2007;54:946-50
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Chu ES, Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005;92:2190-4
   PubMed Web of Science ®Google Scholar
• Abbaszadegan MR, Moaven O, Sima HR, p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol 2008;14:2055-60
   PubMedGoogle Scholar
• Kawakami K, Brabender J, Lord RV, Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11
   PubMed Web of Science ®Google Scholar
• Ikoma D, Ichikawa D, Ueda Y, Circulating tumor cells and aberrant methylation as tumor markers in patients with esophageal cancer. Anticancer Res 2007;27(1B):535-9
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Vallbohmer D, Prenzel K, Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 2009;135:1231-7
   PubMed Web of Science ®Google Scholar
• Melnikov AA, Scholtens D, Talamonti MS, Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol 2009;99:119-22
   PubMed Web of Science ®Google Scholar
• Liggett T, Melnikov A, Yi QL, Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010;116:1674-80
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5
   PubMed Web of Science ®Google Scholar
• Hui AB, Shi W, Boutros PC, Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009;89:597-606
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-18
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006
   PubMed Web of Science ®Google Scholar
• Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009;9:703-11
   PubMed Web of Science ®Google Scholar
• Ahmed FE, Jeffries CD, Vos PW, Diagnostic MicroRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009;6:281-95
   PubMedGoogle Scholar
• Ng EK, Chong WW, Jin H, Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26
   PubMed Web of Science ®Google Scholar
• Zhou H, Guo JM, Lou YR, Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med 2010;88:709-17
   PubMed Web of Science ®Google Scholar
• Tsujiura M, Ichikawa D, Komatsu S, Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Chang P, MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila Pa) 2009;2:807-13
   PubMed Web of Science ®Google Scholar
• Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 2010;10:541-5
   PubMed Web of Science ®Google Scholar
• Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 2010;4:583-6
   PubMed Web of Science ®Google Scholar
• Hibi K, Taguchi M, Nakayama H, Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135-8
   PubMed Web of Science ®Google Scholar